Effect Analysis of PEG-rhG-CSF in Preventing Neutropenia of Small Cell Lung Cancer after Chemotherapy
Objective:To investigate the effect of PEGylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF)in preventing neutropenia of small cell lung cancer after chemotherapy.Method:A total of 200 patients with small cell lung cancer treated with chemotherapy in Beijing Chaoyang Huanxing Cancer Hospital from January 2020 to March 2023 were selected and divided into two groups according to envelope method.The control group(n=98)was treated with Recombinant Human Granulocyte Colony-stimulating Factor(rhG-CSF)after chemotherapy,and the observation group(n=102)was treated with PEG-rhG-CSF after chemotherapy.The incidence of neutropenia,immune function,serum tumor markers and the occurrence of adverse reactions were compared between the two groups.Result:The incidence of neutropenia in observation group was lower than that in control group,the difference was statistically significant(P<0.05).After treatment,the levels of CD3+and CD4+in the observation group were higher than those in the control group,and the levels of CD8+,cyto-keratin 19 fragment(Cyfra21-1),pro-gastrin-releasing peptide(Pro-GRP)and neuron specific enolase(NSE)were lower than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The application of PEG-rhG-CSF after chemotherapy for small cell lung cancer can effectively prevent the occurrence of neutropenia,improve the immune function of the body,inhibit the levels of serum tumor markers,and has good safety.
Small cell lung cancerChemotherapyPEGylated Recombinant Human Granulocyte Colony-stimulating FactorNeutropenia
万方数据
维普
